We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RHHBY Secures FDA Approval for Breast Cancer Treatment
Read MoreHide Full Article
Key Takeaways
Roche wins FDA nod for Wilserdly plus everolimus in ER-positive, HER2-negative, ESR1-mutated breast cancer.
The evERA study showed the combination reduced progression or death risk by 62% versus standard therapy.
Six phase III trials and a pending adjuvant approval decision could expand Wilserdly's market potential.
Roche (RHHBY - Free Report) won FDA approval for Wilserdly (giredestrant) in combination with everolimus for treating adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
The approval covers patients whose disease has recurred during or after adjuvant endocrine therapy or progressed after at least one endocrine-based regimen in the metastatic setting.
Wilserdly is a next-generation, potent, oral selective estrogen receptor degrader (SERD) and full antagonist designed to achieve deep and sustained inhibition of ER signaling.
The approval strengthens Roche’s oncology portfolio with a new treatment option for patients with advanced breast cancer who develop resistance to endocrine therapy. ESR1 mutations, which drive hormone therapy resistance, affect up to 40% of patients with HR-positive metastatic breast cancer.
Wilserdly plus everolimus addresses this by targeting two different signaling pathways and offers an alternative without the need for injections.
More on RHHBY’s Breast Cancer Drug
The approval is supported by positive results from the phase III evERA Breast Cancer study. In adult patients with ESR1-mutated, ER-positive, HER2-negative locally advanced or metastatic breast cancer progressing after prior cyclin-dependent kinase (CDK)4/6 inhibitor therapy, the all-oral combination of Wilserdly plus everolimus reduced the risk of disease progression or death by 62% compared with standard endocrine therapy plus everolimus. The combination significantly prolonged progression-free survival.
Per Roche, Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III evERA study.
The drug is also under FDA review as an adjuvant treatment for adults with ER-positive, HER2-negative stage I, II and III breast cancer at intermediate to high risk of recurrence. The application, supported by phase III lidERA study results, received Priority Review, with an FDA decision expected by Nov. 30, 2026.
If approved in the adjuvant setting, Wilserdly would become the first SERD approved for both adjuvant and advanced ER-positive breast cancer. This could further expand the drug's commercial opportunity and strengthen Roche's presence across different stages of breast cancer treatment.
Roche is advancing Wilserdly's extensive clinical development program, which includes six company-sponsored phase III trials across multiple treatment settings and lines of therapy, to expand its reach among patients with HR-positive breast cancer.
The company is also pursuing additional regulatory filings and development activities in markets outside the United States.
Breast cancer remains a major global health burden, with approximately 2.3 million women diagnosed and 670,000 deaths reported annually. It is the second most common cancer worldwide and the leading cause of cancer-related deaths among women.
We note that Roche’s breast cancer franchise currently comprises Herceptin(trastuzumab) and Kadcyla (trastuzumab emtansine). Strong performance of Phesgo (a fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) has helped RHHBY maintain momentum in its breast cancer franchise.
RHHBY’s Efforts to Broaden Portfolio
Roche delivered solid performance in the first nine months, as strong growth from key products offset declining sales of legacy drugs.
MS drug Ocrevus and ophthalmology drug Vabysmo continued their stellar performances. Growth in hemophilia treatment Hemlibra and breast cancer drug Phesgo also boosted RHHBY’s top line.
Roche’s shares have risen 18.2% year to date compared with the industry’s growth of 26.6%.
Image Source: Zacks Investment Research
Roche also has a strong and diversified pipeline spanning multiple therapeutic modalities.
The company had earlier collaborated with Nurix Therapeutics (NRIX - Free Report) to co-develop and co-commercialize bexobrutideg (NX-5948) across malignant hematology, immunology and neurology indications.
The NRIX deal expands Roche’s hematology pipeline while providing opportunities to advance the therapy across immunology and neurology indications.
RHHBY is also looking to further diversify its portfolio by advancing enicepatide (CT-388), its investigational once-weekly dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes (T2D) and overweight or obesity.
Shares of Novartis have risen 16.2% so far this year. The Zacks Consensus Estimate for 2027 earnings has risen from $9.81 to $9.99 per share over the past 30 days.
Image: Bigstock
RHHBY Secures FDA Approval for Breast Cancer Treatment
Key Takeaways
Roche (RHHBY - Free Report) won FDA approval for Wilserdly (giredestrant) in combination with everolimus for treating adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
The approval covers patients whose disease has recurred during or after adjuvant endocrine therapy or progressed after at least one endocrine-based regimen in the metastatic setting.
Wilserdly is a next-generation, potent, oral selective estrogen receptor degrader (SERD) and full antagonist designed to achieve deep and sustained inhibition of ER signaling.
The approval strengthens Roche’s oncology portfolio with a new treatment option for patients with advanced breast cancer who develop resistance to endocrine therapy. ESR1 mutations, which drive hormone therapy resistance, affect up to 40% of patients with HR-positive metastatic breast cancer.
Wilserdly plus everolimus addresses this by targeting two different signaling pathways and offers an alternative without the need for injections.
More on RHHBY’s Breast Cancer Drug
The approval is supported by positive results from the phase III evERA Breast Cancer study. In adult patients with ESR1-mutated, ER-positive, HER2-negative locally advanced or metastatic breast cancer progressing after prior cyclin-dependent kinase (CDK)4/6 inhibitor therapy, the all-oral combination of Wilserdly plus everolimus reduced the risk of disease progression or death by 62% compared with standard endocrine therapy plus everolimus. The combination significantly prolonged progression-free survival.
Per Roche, Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III evERA study.
The drug is also under FDA review as an adjuvant treatment for adults with ER-positive, HER2-negative stage I, II and III breast cancer at intermediate to high risk of recurrence. The application, supported by phase III lidERA study results, received Priority Review, with an FDA decision expected by Nov. 30, 2026.
If approved in the adjuvant setting, Wilserdly would become the first SERD approved for both adjuvant and advanced ER-positive breast cancer. This could further expand the drug's commercial opportunity and strengthen Roche's presence across different stages of breast cancer treatment.
Roche is advancing Wilserdly's extensive clinical development program, which includes six company-sponsored phase III trials across multiple treatment settings and lines of therapy, to expand its reach among patients with HR-positive breast cancer.
The company is also pursuing additional regulatory filings and development activities in markets outside the United States.
Breast cancer remains a major global health burden, with approximately 2.3 million women diagnosed and 670,000 deaths reported annually. It is the second most common cancer worldwide and the leading cause of cancer-related deaths among women.
We note that Roche’s breast cancer franchise currently comprises Herceptin(trastuzumab) and Kadcyla (trastuzumab emtansine). Strong performance of Phesgo (a fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) has helped RHHBY maintain momentum in its breast cancer franchise.
RHHBY’s Efforts to Broaden Portfolio
Roche delivered solid performance in the first nine months, as strong growth from key products offset declining sales of legacy drugs.
MS drug Ocrevus and ophthalmology drug Vabysmo continued their stellar performances. Growth in hemophilia treatment Hemlibra and breast cancer drug Phesgo also boosted RHHBY’s top line.
Roche’s shares have risen 18.2% year to date compared with the industry’s growth of 26.6%.
Image Source: Zacks Investment Research
Roche also has a strong and diversified pipeline spanning multiple therapeutic modalities.
The company had earlier collaborated with Nurix Therapeutics (NRIX - Free Report) to co-develop and co-commercialize bexobrutideg (NX-5948) across malignant hematology, immunology and neurology indications.
The NRIX deal expands Roche’s hematology pipeline while providing opportunities to advance the therapy across immunology and neurology indications.
RHHBY is also looking to further diversify its portfolio by advancing enicepatide (CT-388), its investigational once-weekly dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes (T2D) and overweight or obesity.
RHHBY’s Zacks Rank and A Stock to Consider
Roche currently carries a Zacks Rank #3 (Hold). A better-ranked large-cap pharma stock is Novartis (NVS - Free Report) , which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Shares of Novartis have risen 16.2% so far this year. The Zacks Consensus Estimate for 2027 earnings has risen from $9.81 to $9.99 per share over the past 30 days.